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ABSTRACT 
Anxiety is an ailment causing personal, social and economic burden. Some drugs are available to provide symptomatic assistance for the 
treatment of anxiety and attempts are being made to find new therapeutic entities and subside associated adverse effects. Approaching natural 
sources, the current study aims to investigate the anxiolytic effects of cardamonin and its effect on the brain GABAergic system. The anxiolytic 
effects of various dose of cardamonin were investigated using the elevated plus maze apparatus and possible motor disabilities were evaluated 
trough open field test. Possible impact on GABAergic system was investigated using the ELISA. Fourteen days treatment with cardamonin (5.0 
and 10.0 mg/kg, i.p.) in mice significantly (p < 0.0001) increased and the percentages of open arm entry and open arm time compared to 
respective vehicle control group. Cardamonin show no influence on gross locomotor movement in open field test. Treatment with cardamonin 
significantly (p < 0.0001) increased levels of GABA in brain of treated mice compared to control mice. This study provided evidence on the 
anxiolytic potency of the cardamonin and revealed its action mechanism of regulating the GABA level in mouse brain. 
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INTRODUCTION 
Nervous ailments particularly depression and anxiety are 
predominant all over the world, that affect the value of daily 
lives and enhance the risk for additional medical 
complications. It is projected that by 2020 such behavioral 
disorder will account for about 15% of the universal burden 
of disease 1.  Anxiety has been defined as “a psychological 
and physiological state characterized by somatic, emotional, 
cognitive and behavioral components”. It is an emotional 
state, unpleasant in nature, associated with uneasiness, 
discomfort and fear about some defined or undefined future 
threat 2. The personal, social and economic expenditures 
linked with this mental disorder is noticeably high. Some 
drugs are available to provide appropriate symptomatic 
assistance for the treatment of anxiety; however these are 
associated with ample adverse effects like ataxia, drug 
dependence, drowsiness, withdrawal syndrome, drug 
interactions etc 3. Attempts are being made to find new 
therapeutic entities and subside these adverse effects. 
Subsequently, there is excessive interest in exploration of 
appropriate and harmless agents from natural source and in 
the recent years; progresses are being made in this regard 4.  
Cardamonin, chemically known as (2’, 4’-dihydroxy-6’-
methoxychalcone) is a naturally occurring chalcone, 
foremost isolated from seeds of Amomum subulatum and 
later from other plant species, such as Alpinia henryi, Alpinia 
katsumadai, Alpinia rafflesiana, Boesenbergia pandurata and 
Campomanesia adamantium 5. Cardamonin is known to 
exhibit many pharmacological activities including anti-
inflammatory, anti-mutagenic, anti-neoplastic, anti-
proliferative, anti-tumor, in vitro anti-HIV, vasorelaxant, 
hypoglycemic, anti-infectious and anti-platelet activities 6. It 
is also known to possess potential beneficial effects on 
various neurological disorders including anti-nociceptive 
property 6, neuroprotection of PC12 cells against oxidative 
damage 7 and ameliorative effect on hyperalgesia and 
allodynia in a mouse model of chronic constriction injury-
induced neuropathic pain 8. The quest for potential health 
applications of cardamonin particularly in relation to 
neuroprotection seems to grow in the near future as shown 
clearly by the increasing number of ongoing research. The 
current study was carried out with the aim to investigate the 
anxiolytic effects of cardamonin and the effect on 
cardamonin on the brain GABAergic system. 
MATERIALS AND METHODS 
Animals 
Rajput et al                                                                                                                Journal of Drug Delivery & Therapeutics. 2019; 9(1):248-251 
ISSN: 2250-1177                                                                                     [249]                                                                                      CODEN (USA): JDDTAO 
Adult Swiss albino mice (25–30 g) were used in this study. 
One week period was given to the animals to acclimatize to 
the new environment (25 ± 5 ˚C, 50 ± 5% humidity and a 
12/12-h light/dark cycle starting at 08:00 A.M. Food and 
water were provided ad libitum. Seven days acclimatization 
was provided to the animals before start of experiment. All 
the experiments were carried out according to the animal 
care guidelines as provided by National Institute of Health 
and after getting authorization from Institutional Animal 
Ethics Committee constituted as per the guidelines of 
CPCSEA. 
Drugs and solutions 
Cardamonin or 2′, 4′-dihydroxy-6′-methoxychalcone with 
the purity of ≥98%, dimethyl sulphoxide (DMSO), tween 20 
and estazolam was purchased from Sigma Aldrich (Sigma-
Aldrich Chemicals Pvt. Ltd. Bengaluru, India). Cardamonin 
was freshly prepared by dissolving in DMSO, tween 20 and 
distilled water at a ratio of 5:5:90 (v/v). Estazolam (6 mg) 
was suspended in 0.5% sodium CMC aqueous solution in a 
100 ml constant volume [8]. All other drugs were dissolved 
in distilled water. The doses for all freshly prepared drug 
solutions were expressed in terms of their free bases. 
Treatment schedule 
The animals were randomly allocated into various groups of 
six mice each. Animals of group I served as vehicle control 
and treated with vehicle for cardamonin (1 ml/kg, i.p.). Mice 
of group II, III and IV were treated with cardamonin at the 
dose of 2.5, 5.0 and 10.0 mg/kg, i.p. respectively and group V 
served as standard and treated with estazolam (1.5 mg/kg, 
p.o.) once daily for fourteen days. Behavioral tests were 
conducted on the fourteenth day after three hours of last 
treatment.  
Evaluation of antianxiety activity  
Elevated plus maze test (EPM)  
The plus maze was composed of two open arms (42.5 cm × 
10.0 cm) and two closed arms (42.5 cm × 10.0 cm × 22.5 cm), 
extending from a central platform (10.0 cm × 10.0 cm) and 
elevated to a height of 50.0 cm above the floor. The entire 
maze was made of clear Plexiglas. Mice were individually 
placed in the center of the maze facing an open arm. Arm 
entries were defined as the placement of all four paws into 
an arm. Animal activities were recorded during a 5 min 
observation period, including the number of open and closed 
arm entries (OE and CE), the duration in open and closed 
arms (OT and CT) and the percentages of open arm entry 
and open arm time (OE% and OT%). The formulae of OE% = 
OE/(OE + CE) × 100% and OT% = OT/(OT + CT) × 100% 
were calculated. After each trial, the apparatus was cleaned 
with 75% alcohol solution 9. 
Open field test 
Open field test was conducted to rule out the possibility of 
motor disabilities. One hour after the probe trial, mice were 
relocated to an open field apparatus (60 cm × 40 cm × 28 
cm) with the flooring partitioned into 12 square. During the 
session of open field testing (5 min), the number of rearing 
(vertical activity) and crossing (horizontal activity) 
responses were recorded manually 10. 
Biochemical estimation 
GABA assay 
Ensuing behavioral tests mice were beheaded and shifted 
onto dry ice. The rapid dissection of the brain was done and 
rinsed with ice cold normal saline (0.9% sodium chloride) 
and frozen till the biochemical estimation. The frozen mouse 
brain tissue was homogenized in 10 vol (w/v) of ice normal 
saline. The homogenate was centrifuged at 3000 rpm at 4 ° 
for 10 min and the supernatant was collected. GABA levels in 
the brain were estimated using the GABA ELISA kit (Aviva 
Systems Biology, CA, USA). The GABA contents were 
expressed as microgram per kilogram of brain. 
Statistical analysis 
Results were expressed as mean ± S.E.M. The data were 
analyzed by one way analysis of co-variance (ANCOVA) 
tracked by Tukey's multiple comparison tests. Probability 
values less than 0.05 were considered statistically significant 
in all the cases. 
RESULTS AND DISCUSSION 
Effect of cardamonin treatment on performance of EPM 
Results were obtained from the arm entry experiments and 
the percentages of open arm entry and open arm time were 
compared. One way ANCOVA followed by post-hoc test 
demonstrated that medium (5.0 mg/kg) and high dose (10.0 
mg/kg) cardamonin and estazolam (1.5 mg/kg) significantly 
(p < 0.0001) increased OT% [F(4, 25) = 256.80, p < 0.0001, 
R2 = 0.9762] and OE% [F(4, 25) = 184.90, p < 0.0001, R2 = 
0.9673] compared to respective vehicle control group. 
Treatment with cardamonin (2.5 mg/kg) did not influence 
OE% and OT% (Figure 1). 
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Figure 1: Effects of cardamonin on OE% and OT% in elevated plus maze apparatus. 
Results are expressed as Mean ± S.E.M.; n = 6 in each group. Data was analyzed by one way repeat measure ANCOVA followed by Tuckey’s multiple 
comparison test. Significance: *p< 0.0001 when compared with VC group, Car: Cardamonin treated group; VC: Vehicle control. 
 
Effect of cardamonin on locomotor activity in open field 
test 
Motivational difference in the training period may relate for 
differences in inhibitory avoidance at testing. Hence open 
field study was performed to evaluate locomotor ability of 
the animals that would alter escape latency. One way 
ANCOVA of open field data revealed that none of the 
treatment alter the number of crossing or rearing responses 
in a subsequent open field test session, signifying no 
influence on gross locomotor movement at testing [F(4, 25) 
= 0.12, p = 0.9893, R2 = 0.0188] and number of rearing [F(4, 
25) = 2.89, p = 0.9859, R2 = 0.3164] (Table 1). 
 
Table 1: Effects of cardamonin on locomotor activity and number of rearing in open field test. 
Group Treatment No. of locomotor counts No. of rearings 
Vehicle control Vehicle (1 ml/kg) 123.38 ± 3.01 28.21 ± 0.62 
Cardamonin treated 
Car (2.5 mg/kg) 122.86 ± 3.32 30.66 ± 0.57 
Car (5.0 mg/kg) 124.37 ± 2.96 30.18 ± 0.72 
Car (10.0 mg/kg) 122.40 ± 3.57 28.90 ± 0.68 
Standard Estazolam (1.5 mg/kg) 125.07 ± 2.88 30.54 ± 0.59 
Results are expressed as Mean ± S.E.M.; n = 6 in each group. Data was analyzed by one way repeat measure ANCOVA followed by Tuckey’s 
multiple comparison test. Car: Cardamonin treated group. 
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Estimation of effect of cardamonin on brain GABAergic 
activity 
Treatment with cardamonin (5.0 and 10.0 mg/kg) and 
estazolam (1.5 mg/kg) significantly increased levels of GABA 
in brain of treated mice (p < 0.0001) compared to control 
mice. Treatment with cardamonin (2.5 mg/kg) did not 
influence levels of GABA [F(4, 25) = 415.50, p < 0.0001, R2 = 
0.9852] (Figure 2). 
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Figure 2: Effects of cardamonin on GABA levels in brain of mice. 
Results are expressed as Mean ± S.E.M.; n = 6 in each group. Data was analyzed by one way repeat measure ANCOVA followed by Tuckey’s multiple 
comparison test. Significance: *p< 0.0001 when compared with VC group, Car: Cardamonin treated group; VC: Vehicle control. 
 
Anxiety disorders often accompany the abnormal expression 
of neurotransmitter such as NE, DA, 5-HT and GABA. GABA 
has been considered the major inhibitory neurotransmitter 
in the mammalian central nervous system, and enhanced 
GABAergic can be effective in treating anxiety disorders 11. In 
this study, whereas the GABA level of cardamonin treated 
group at medium- and high-dose were significantly 
increased, indicating that cardamonin increases the GABA to 
inhibit the excitability of the central nervous system. In 
conclusion, this study indicated anxiolytic potency of 
cardamonin and its action mechanism of increasing GABA 
and future research will aim to offer more insights into this 
feature. 
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